Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBT Margin (2016 - 2025)

Guided Therapeutics' EBT Margin history spans 15 years, with the latest figure at 1236.67% for Q3 2025.

  • For Q3 2025, EBT Margin changed N/A year-over-year to 1236.67%; the TTM value through Sep 2025 reached 1477.53%, up 418300.0%, while the annual FY2024 figure was 34528.57%, 3096837.0% down from the prior year.
  • EBT Margin for Q3 2025 was 1236.67% at Guided Therapeutics, down from 691.45% in the prior quarter.
  • Across five years, EBT Margin topped out at 394.74% in Q3 2021 and bottomed at 65200.0% in Q4 2024.
  • The 5-year median for EBT Margin is 3950.0% (2023), against an average of 15440.85%.
  • The largest annual shift saw EBT Margin surged 3320000bps in 2022 before it tumbled -6399375bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 740.0% in 2021, then crashed by -4864bps to 36733.33% in 2022, then skyrocketed by 97bps to 1206.25% in 2023, then plummeted by -5305bps to 65200.0% in 2024, then surged by 98bps to 1236.67% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's EBT Margin are 1236.67% (Q3 2025), 691.45% (Q2 2025), and 65200.0% (Q4 2024).